Psoriasis Raptiva

More information on PSORIASIS ...
What Are Some Promising Areas of Psoriasis Research?
Significant progress has been made in understanding the inheritance of psoriasis. A number of genes involved in psoriasis are already known or suspected. In a multifactor disease (involving genes, environment, and other factors), variations in one or more genes may produce a greater likelihood of getting the disease. Researchers are continuing to study the genetic aspects of psoriasis. Since discovering that inflammation in psoriasis is triggered by T cells, researchers have been studying new treatments that quiet immune system reactions in the skin. Among these are treatments that block the activity of T cells or block cytokines (proteins that promote inflammation). Several of these drugs are awaiting approval by the U.S. Food and Drug Administration (FDA).

Advances in laser technology are making it possible for doctors to experiment with laser light treatment of localized plaques. A UVB laser was recently tested in a study that was conducted at several medical centers. Although improvements in the skin were noted, this treatment is not without possible side effects. In some patients, the skin became inflamed, blistered, or discolored following treatment. - NIAMS

Top Resource Searches For:

Psoriasis Raptiva

Marketed Product: RAPTIVA_
... " RAPTIVA_ Product. " Psoriasis Facts ... in the reduction of symptoms associated with psoriasis. RAPTIVA is administered once-weekly via subcutaneous injection ...

CommentWire by Datamonitor - Psoriasis: Raptiva nears kick-off
Breaking news with business, finance, company and internet comment articles with opinion and analysis of the latest stories ... Psoriasis: Raptiva nears kick-off ... 1:20 PM GMT (Datamonitor) - The launch of Raptiva for psoriasis will upgrade Xoma's [XOMA] stock and improve its cash ...

Efalizumab (Raptiva) bei Psoriasis
Efalizumab (Raptiva) bei Psoriasis ... Efalizumab (Raptiva®) in der Langzeitbehandlung von Psoriasis ... Wirkstoff: Efalizumab (Raptiva®) ist ein T-Zellmodulator und hemmt die Aktivierung der T-Zellen, die für die ...

National Psoriasis Foundation to Testify for Raptiva Approval
Password. News and Events. News. Federal Advisory Committee Recommends Approval of New Psoriasis Drug. Final approval could come by end of October. First posted Sept. 10, 2003. Last updated Sept. 23, 2003. In a unanimous vote on Sept. ... approval of the psoriasis drug efalizumab (brand name Raptiva) for the treatment of moderate to severe stable plaque psoriasis. The Dermatologic and Ophthalmic ...

RAPTIVA for Psoriasis: FAQs
Common questions about RAPTIVA psoriasis treatment. RAPTIVA for plaque psoriasis brought to you by Genentech.

Psoriasis-Netz - Die vielen Seiten der Schuppenflechte: Startseite
... 26.06.2004. Efalizumab (Raptiva) Psoriasis arthritis ... Empfehlen Sie das Psoriasis-Netz Bekannten oder Patienten ...

Raptiva(R) (Efalizumab) Receives Approval for Moderate-to-Severe Plaque Psoriasis in Switzerland
Raptiva(R) (Efalizumab) Receives Approval for Moderate-to-Severe Plaque Psoriasis in Switzerland ... First Approval of Raptiva for Serono GENEVA, March 16 /PRNewswire-FirstCall ... to-severe plaque psoriasis. Raptiva is the first biological therapy for psoriasis that is approved ...

DERMATOLOGIC AND OPTHALMIC DRUGS ADVISORY COMMITTEE MEETING
... Clinical Development of Raptiva: Completed Psoriasis Studies...... 23 ... be safe and effective for the treatment of psoriasis. Raptiva has a rapid onset of action and is well ...

Raptiva(R) (Efalizumab) Receives Approval for Moderate-to-Severe Plaque Psoriasis in Switzerland - ADVFN News ...
... Raptiva(R) (Efalizumab) Receives Approval for Moderate-to-Severe Plaque Psoriasis in ... severe plaque psoriasis. Raptiva is the first biological therapy for psoriasis that is ...

RAPTIVA_ — Psoriasis Facts
(Efalizumab) Psoriasis Facts. Psoriasis is a chronic skin disorder that affects approximately 4.5 million people in the United States, according to the National Psoriasis Foundation.

Genentech: Products - Product Information - RAPTIVA
... RAPTIVA is approved for the treatment of chronic moderate-to-severe plaque psoriasis in adults ... of symptoms associated with psoriasis. RAPTIVA is administered once-weekly via ...

Chronic Pain | Psoriasis Raptiva